STAT Plus: Lawmakers search extra data on how FDA inspects vegetation in China and India

Amid ongoing curiosity amongst People to import medication from different international locations in addition to persevering with concern a few spate of recalled blood stress medicines manufactured abroad, Home and Senate lawmakers have requested the FDA to clarify the way it protects the pharmaceutical provide chain. On the identical time, a bipartisan group from the Home desires the Authorities Accountability Workplace to evaluate the FDA inspection program.

In separate letters despatched late final week, the lawmakers cited current information stories about ongoing manufacturing issues at firms in China and India, which account for almost all of the lively pharmaceutical substances utilized in medicines which might be shipped to the U.S. Additionally they pointed to a 2016 GAO report that discovered FDA oversight of international services was missing.

Unlock this text by subscribing to STAT Plus and luxuriate in your first 30 days free!


What’s it?

STAT Plus is a premium subscription that delivers each day market-moving biopharma protection and in-depth science reporting from a group with a long time of trade expertise.

What’s included?

Authoritative biopharma protection and evaluation, interviews with trade pioneers, coverage evaluation, and first appears to be like at innovative laboratories and early stage analysis
Subscriber-only networking occasions and panel discussions throughout the nation
Month-to-month subscriber-only dwell chats with our reporters and specialists within the discipline
Discounted tickets to trade occasions and early-bird entry to trade stories